OTLK - Outlook Therapeutics, Inc.
0.8850 +0.01 (1.72%)
After hours: 6:03PM EDT
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.7479 |
| Open | 0.8550 |
| Bid | 0.8700 x 1000 |
| Ask | 0.8850 x 800 |
| Day's Range | 0.8169 - 0.9400 |
| 52 Week Range | 0.4990 - 3.2000 |
| Volume | 4,997,320 |
| Avg. Volume | 592,045 |
| Market Cap | 79.499M |
| Beta (5Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5740 |
| Earnings Date | Aug 12, 2020 - Aug 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.13 |
- GlobeNewswire
Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics, Inc. (OTLK) (the Company), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has entered into a Stock Purchase Agreement with Syntone Ventures LLC for a private placement of $16.0 million of common stock at a price of $1.00 per share. In addition, Outlook Therapeutics entered into a joint venture agreement with Syntone Technologies Group Co. Ltd. (“Syntone”) to form a PRC joint venture to develop and commercialize ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in China pursuant to a license agreement to be entered into between Outlook Therapeutics and the joint venture.
- Simply Wall St.
Some Analysts Just Cut Their Outlook Therapeutics, Inc. (NASDAQ:OTLK) Estimates
Today is shaping up negative for Outlook Therapeutics, Inc. (NASDAQ:OTLK) shareholders, with the analysts delivering a...
- GlobeNewswire
Outlook Therapeutics Reports Financial Results for the Second Quarter of Fiscal Year 2020 and Provides Corporate Update
Company remains on track to report topline data results from NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of.
- GlobeNewswire
Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has bolstered its Board of Directors with the appointments of Prof. Dr. Gerd Auffarth and Mr. Julian Gangolli. “We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” stated Lawrence A. Kenyon, President, CEO and CFO, Outlook Therapeutics.
- Zacks
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
- GlobeNewswire
Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence A. Kenyon, President, CEO and CFO of Outlook Therapeutics, will present at the April 2020 Virtual Investor Summit on Wednesday, April 22, 2020 at 10:30 AM ET. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (outlooktherapeutics.com).
- GlobeNewswire
Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2
Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab,.
- Simply Wall St.
Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98%
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like...
- GlobeNewswire
Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved
Outlook Therapeutics intends to market ONS-5010 as LYTENAVA™ (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet age-related macular degeneration (wet AMD). CRANBURY, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval of the Tradename for ONS-5010 as LYTENAVA™ (bevacizumab-vikg).
- GlobeNewswire
Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 7,598,426 shares of its common stock, at a combined purchase price of $1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately $7.72 million. The Company also issued to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock. The warrants have an exercise price of $0.9535 per share of common stock, are exercisable on the date of issuance, and will expire four years following the date of issuance.
- ACCESSWIRE
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK
NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Levi & Korsinsky announces it has commenced an investigation of Outlook Therapeutics, Inc. (NASDAQ:OTLK) concerning possible breaches of fiduciary duty. ...
- GlobeNewswire
Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering priced at-the-market under Nasdaq rules, of 7,598,426 shares of its common stock, at a combined purchase price of $1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately $7.72 million. The Company also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock.
- GlobeNewswire
INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims.
NEW YORK, Feb. 18, 2020 -- Fields Kupka & Shukurov LLP is investigating potential securities violations and breach of fiduciary duty claims involving the board of directors.
- GlobeNewswire
Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020
CRANBURY, N.J., Feb. 14, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first.
- GlobeNewswire
Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference
CRANBURY, N.J., Feb. 04, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first.
- GlobeNewswire
Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. (“BioLexis”), its largest stockholder, and MTTR, LLC (“MTTR”), its development partner for ONS-5010, to better align the interests of all parties with the Company’s common stockholders and support the continued development of ONS-5010.
- GlobeNewswire
Outlook Therapeutics Announces Completion of Warrant Restructuring
CRANBURY, N.J., Dec. 26, 2019 -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first.
- Benzinga
The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
- GlobeNewswire
Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has taken action to improve the Company’s balance sheet through two separate transactions. Effective December 23, 2019, with consent of the required holders of the Outlook Therapeutics warrants issued in April 2019 (the “Warrants”) in an underwritten public offering, the Company amended the Warrants to reduce the exercise price to $0.232 per warrant and allow for the immediate exercise of the Warrants.
- GlobeNewswire
Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019
Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020Enrollment in the NORSE 2 study underwaySPA agreement reached.
- GlobeNewswire
Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010
ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2). SPAs for clinical trial protocols for NORSE 4 for branch retinal vein occlusion (“BRVO”) and NORSE 5 and NORSE 6 for diabetic macular edema (“DME”) indicate FDA agreement on overall protocol design (entry criteria, dose selection, endpoints and planned analyses). CRANBURY, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has received agreement from the U.S. Food and Drug Administration (“FDA”) on three Special Protocol Assessments (“SPAs”) for three additional registration clinical trials for its ongoing Phase 3 program for ONS-5010, an investigational ophthalmic formulation of bevacizumab.
- Simply Wall St.
What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)?
A look at the shareholders of Outlook Therapeutics, Inc. (NASDAQ:OTLK) can tell us which group is most powerful...
- GlobeNewswire
Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference
CRANBURY, N.J., Sept. 11, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019.
- GlobeNewswire
Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference
CRANBURY, N.J., Aug. 27, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st.
- GlobeNewswire
Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD
Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis®) for wet AMD. “We are pleased with the building momentum in our two ongoing Phase 3 clinical trials for ONS-5010, including completing enrollment in NORSE 1. The study is the first of two ongoing, adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab for wet AMD.
